Literature DB >> 16911469

Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures.

Shira Zelber-Sagi1, Dorit Nitzan-Kaluski, Zamir Halpern, Ran Oren.   

Abstract

BACKGROUND/AIMS: Only a few studies have assessed the epidemiology of non-alcoholic fatty liver disease (NAFLD). The aim was to evaluate the prevalence of primary NAFLD in a population-based study in Israel and to determine independent risk factors.
METHODS: A cross-sectional study of a subsample of the Israeli national health survey (n=352). Individuals with a known etiology for secondary NAFLD were excluded. Each participant underwent an abdominal ultrasound, biochemical tests and an anthropometric evaluation.
RESULTS: Three hundred and twenty-six subjects (53.4% male, mean age 50.5+/-10.3 standard deviaton [SD]) met the inclusion criteria. The prevalence of primary NAFLD was 30% (25-35% 95% confidence intervals [CI]). NAFLD was more prevalent in men than women (38% vs. 21%; P=0.001). Compared with ultrasonography, the sensitivity of serum alanine transaminase (ALT) for the diagnosis of primary NAFLD was 8.2%. Risk factors independently associated with NAFLD included male gender (odds ratios (OR)=2.8, 95% CI 1.5-5.3), abdominal obesity (OR=2.9, 95% CI 1.3-6.4), homeostasis model assessment (OR=5.8, 95% CI 2.0-17.2), hyperinsulinemia (OR=2.3, 95% CI 1.2-4.3, P=0.01) and hypertriglyceridemia (OR=2.4, 95% CI 1.3-4.5).
CONCLUSIONS: NAFLD is prevalent in the general Israeli population and closely related to the metabolic syndrome. The use of ALT as a marker for NAFLD seriously underestimates its prevalence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911469     DOI: 10.1111/j.1478-3231.2006.01311.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  82 in total

1.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

2.  The relationship between arterial stiffness and nonalcoholic fatty liver disease.

Authors:  Yong-Jae Lee; Jae-Yong Shim; Byung-Soo Moon; Youn-Ho Shin; Dong-Hyuk Jung; Jung-Hyun Lee; Hye-Ree Lee
Journal:  Dig Dis Sci       Date:  2011-07-13       Impact factor: 3.199

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

4.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 6.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

7.  Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study.

Authors:  Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Meredith C Foster; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox
Journal:  J Gastroenterol Hepatol       Date:  2008-06       Impact factor: 4.029

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 9.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

10.  Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease.

Authors:  Ancha Baranova; Karen Schlauch; Hazem Elariny; Mohammed Jarrar; Chase Bennett; Clare Nugent; Shobha J Gowder; Zahra Younoszai; Rochelle Collantes; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.